DLinDMA
(Synonyms: 1,2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane) 目录号 : GC33476
DLinDMA 是以稳定的核酸脂质颗粒为基准的关键脂质组分。
Cas No.:871258-12-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark. DLinDMA can be used to deliver siRNA[1].
DLinDMA liposomal formulation was nontoxic at lower concentrations. A significant decrease in cell proliferation was only observed at the highest concentration 200 µM for DOTAP and at concentrations ranging from 25 to 200 µM for DLinDMA liposomal formulations[2]. In a macrophage cell-line, LNP containing DLinKC2-DMA, DLinKDMA, or DLinDMA, which lack ester linkages, are not vulnerable to lipase digestion and facilitate much more potent gene silencing[3].
As a key lipid component of nucleic acid lipid granules (SNALP), DLinDMA can deliver small interfering RNA (siRNA) in mice[1].
References:
[1]. Semple SC, Akinc A,et,al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17. PMID: 20081866.
[2]. Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095. doi: 10.2217/nnm-2020-0477. Epub 2021 May 7. PMID: 33960213; PMCID: PMC8162161.
[3]. Lin PJ, Tam YY, et,al.Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013 Feb;9(2):233-46. doi: 10.1016/j.nano.2012.05.019. Epub 2012 Jun 12. PMID: 22698807.
DLinDMA 是以稳定的核酸脂质颗粒为基准的关键脂质组分。 DLinDMA 可用于递送 siRNA[1]。
DLinDMA 脂质体制剂在较低浓度下无毒。仅在 DOTAP 的最高浓度 200 µM 和 DLinDMA 脂质体制剂的浓度范围为 25 至 200 µM 时观察到细胞增殖显着下降[2]。在巨噬细胞系中，含有缺乏酯键的 DLinKC2-DMA、DLinKDMA 或 DLinDMA 的 LNP 不易被脂肪酶消化，并促进更有效的基因沉默[3]。
作为核酸脂质颗粒 (SNALP) 的关键脂质成分，DLinDMA 可以在小鼠体内递送小干扰 RNA (siRNA)[1]。
| Cell experiment [1]: | |
|
Cell lines |
HEK293 cells and SK-N-SH cells |
|
Preparation Method |
Cells were treated with DLinDMA liposomes at concentrations ranging from 1.56 to 200 µM. Transit LT1 and PEI max were used as positive controls. |
|
Reaction Conditions |
DLinDMA 1.56 to 200 µM for 48h |
|
Applications |
Cell proliferation assay results showed that these liposomal formulations are nontoxic at lower concentrations. A significant decrease in cell proliferation was only observed at the concentrations ranging from 25 to 200 µM for DLinDMA liposomal formulations |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
Mice received a single dose of LNP( Consisting of DLinDMA) -formulated Factor VII siRNA through bolus tail vein injection and serum was collected from animals 24 h after administration to analyze Factor VII protein level. |
|
Applications |
As a key lipid component of nucleic acid lipid granules (SNALP), DLinDMA can deliver small interfering RNA (siRNA) in mice. |
|
References: [1]. Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095. doi: 10.2217/nnm-2020-0477. Epub 2021 May 7. PMID: 33960213; PMCID: PMC8162161. |
|
| Cas No. | 871258-12-7 | SDF | |
| 别名 | 1,2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C | ||
| 分子式 | C41H77NO2 | 分子量 | 616.06 |
| 溶解度 | Ethanol : ≥ 100 mg/mL (162.32 mM);DMSO : < 1 mg/mL (insoluble or slightly soluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6232 mL | 8.1161 mL | 16.2322 mL |
| 5 mM | 0.3246 mL | 1.6232 mL | 3.2464 mL |
| 10 mM | 0.1623 mL | 0.8116 mL | 1.6232 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet